About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR

About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Disclosure to Stock Exchange
  - Annual Reports

 Biocon's Preparedness For CoViD-19


 Annual Report 2019

Annual Report 2018

  - Biocon's Journey of Fortitude
  - Biocon Profile
  - CMD Profile
  - Video Gallery

  Biocon Academy



Biocon Limited is a globally recognized, innovation-led organization that is enabling access to high quality, advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.

We are driven by the belief that the pharmaceuticals industry has a humanitarian responsibility to provide essential drugs to patients who are in need and to do so with the power of innovation. In line with this belief, Biocon has developed and commercialized a differentiated portfolio of novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as, generic formulations in the U.S. and Europe. We are a leading global player for biosimilars and APIs for statins, immunosuppressants and other specialty molecules, with customers in over 120 countries.

Our subsidiary Biocon Biologics is engaged in developing high quality, affordable biosimilars aimed at expanding patient access to a cutting-edge class of therapies across the world. It is uniquely positioned as a fully integrated 'pure play' biosimilars organization globally. Biocon Biologics aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules, including 11 partnered with Mylan, several with Sandoz and many being developed independently. A leading global insulins player with over 15 years of experience in addressing the needs of diabetes patients, it has provided over 2 billion doses of recombinant human insulin (rh-insulin) worldwide, thus far. To enable universal access to high quality insulin, it is offering rh-insulin at less than 10 US cents / day for direct procurement by governments in low and middle-income countries.



Biocon Q4FY20 Performance Highlights by Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

Biocon Corporate Overview
Stock Update

Company Announcements


June 01, 2020 
Biocon's* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi's Four Device Patents for Lantus® SoloSTAR®

May 27, 2020 
Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients

May 19, 2020 
Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab

May 14, 2020 
Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr

  Media Coverage  

May 19, 2020:
Covid provides larger opportunity to shape the biosimilar landscape

May 16, 2020:
Will invest Rs2,000 crore in small molecules in 3-4 years

Mar 12, 2020:
Biocon wins patent case against Sanofi

Mar 10, 2020:
Biocon's cancer biosimilar gets US FDA acceptance for review







Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved